



RECEIVED

MAR 07 2003

#142  
doi  
3/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Keith D. ALLEN

Serial No.: 09/900,700

Filed: July 6, 2001

Title: Transgenic Mice Containing CRFR2  
Corticotropin-Releasing Factor Receptor  
Gene Disruptions

Group Art Unit: 1632

Examiner: Paras, Jr., Peter

Customer No. 26619

Docket/Order No. R-616

Date: February 24, 2003

AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed October 23, 2002 in connection with the above-identified application, Applicant requests entry and consideration of the following amendments and remarks. Applicant submits concurrently herewith a Petition for the Extension of Time under 37 CFR 1.136(a) for response to the Office Action for a period of one month from January 23, 2003 up to and including February 24, 2003, as February 23, 2003 is a Sunday.

THE AMENDMENTS

In the Claims:

Please cancel claims 8, 10 and 17-22.

Please add claims 24-29 below.

24. (New) A transgenic mouse whose genome comprises a disruption in an endogenous CRFR2 gene, wherein where the disruption is homozygous, the transgenic mouse exhibits decreased activity, relative to a wild-type mouse.
25. (New) The transgenic mouse of claim 24, wherein the decreased activity is characterized by a decrease in distance traveled in an open field test.

03/06/2003 ZJUHR1 00000105 501271 09900700

01 FC:2251 55.00 CH